Article Text

Download PDFPDF
▼Atovaquone + proguanil for malaria prophylaxis
  • Relevant BNF section: 5.4.1

Abstract

&#9660Atovaquone + proguanil* (Malarone - GlaxoSmithKline) is a fixed-dose combination of two antiparasitic drugs. In 1996, it was licensed in the UK for the treatment of acute, uncomplicated falciparum malaria. Earlier this year, the combination was licensed additionally for prophylaxis of falciparum malaria. The manufacturer claims that, when used for prophylaxis, atovaquone + proguanil "offers 97% efficacy with a side effect profile similar to placebo". Here, we assess these claims and review the place of atovaquone + proguanil as prophylaxis for non-immune people travelling from the UK.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 5.4.1

View Full Text

Footnotes